The role of PTCy/MMF/CNI as the standard of care for GvHD prophylaxis in the MUD setting скачать в хорошем качестве

The role of PTCy/MMF/CNI as the standard of care for GvHD prophylaxis in the MUD setting

In this video, Leonido Luznik, MD, Johns Hopkins University School of Medicine, Baltimore, MD, shares some insights into the benefits of using post-transplant cyclophosphamide/mycophenolate mofetil/calcineurin inhibitors (PTCy/MMF/CNI) as a standard of care (SOC) for graft-versus-host disease (GvHD) prophylaxis. Dr Luznik comments on the advantages of this approach, and further discusses the need for more randomized trials in this space. This interview took place at The 8th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2023), held in Berlin, Germany. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.